Introduction
Legionella pneumophila is a facultative intracellular bacterial pathogen that causes 80-85% of the cases of Legionnaires' disease, a serious and often fatal form of pneumonia (1, 2) . Patients with Legionnaires' disease develop both humoral and cell-mediated immune responses to L. pneumophila (3) (4) (5) .
Cell-mediated immunity appears to play a vital role in host defense. Activated human monocytes and alveolar macrophages inhibit the intracellular multiplication of L. pneumophila (5) (6) (7) (8) (9) . Humoral immunity appears to play a lesser role in host defense (3, 4) .
The guinea pig is an excellent animal model for the study of Legionnaires' disease. When exposed to aerosols containing L. pneumophila, guinea pigs develop a pneumonic illness that is clinically and pathologically similar to Legionnaires' disease in humans (10) (11) (12) (13) (14) .
Previous studies from this laboratory have demonstrated that guinea pigs immunized with a sublethal aerosolized dose of wild-type L. pneumophila, or with an aerosolized dose of an avirulent mutant L. pneumophila develop humoral and cellmediated immune responses to wild-type L. pneumophila antigens, and protective immunity against lethal aerosol challenge with wild-type L. pneumophila (15, 16) . To identify immunoprotective antigens of L. pneumophila, we have focused our attention on native antigens recognized by the lymphocytes of such immune guinea pigs. Previous studies have identified two such antigenic preparations: the major secretory protein (MSP)1 of L. pneumophila and L. pneumophila membranes (16, 17) .
A previous study from this laboratory explored the capacity of MSP to induce immune responses in the guinea pig. This study demonstrated that MSP is an immunoprotective molecule (17) . This study showed that guinea pigs immunized subcutaneously with MSP develop humoral and cell-mediated immune responses to MSP, and protective immunity against lethal aerosol challenge with L. pneumophila.
Although MSP is an immunoprotective molecule, it is not a virulence determinant in the guinea pig model ofLegionnaires' disease (18) . We have shown that an isogenic MSP-negative strain of L. pneumophila is as virulent for guinea pigs as the parental MSP-positive strain (18) . Moreover, we have shown that naturally occurring species of Legionella that do not produce MSP are nevertheless virulent (19) . That guinea pigs immunized with a sublethal dose of such species develop protective immunity against the vaccine strain has suggested the existence ofother immunoprotective molecules ofLegionella (19) .
In the present study, we have examined the capacity of L. pneumophila membranes to induce immune responses in the guinea pig. First, we shall demonstrate that immunization of guinea pigs with L. pneumophila membranes induces strong cell-mediated immune responses to L. pneumophila membrane antigens and protective immunity against lethal aerosol challenge with L. pneumophila. Secondly, we shall demonstrate that L. pneumophila membranes induce protective immunity independent of MSP, since (a) the membranes do not contain MSP, (b) immunization of guinea pigs with membranes does not induce an immune response against MSP, and (c) immunization of guinea pigs with membranes of MSPnegative L. pneumophila induces protective immunity comparable to that of immunization with membranes of MSP-positive L. pneumophila. Finally, we shall show that immunization ofguinea pigs with formalin-killed L. pneumophila, in contrast to L. pneumophila membranes, does not induce strong cellmediated immune responses or protective immunity against lethal aerosol challenge with L. pneumophila. This study demonstrates that L. pneumophila membranes contain immunoprotective molecules distinct from MSP and that these membranes have potential as a vaccine against Legionnaires' disease.
Methods
Media. Each liter ofalbumin yeast extract broth was prepared with 10 g of Aces (Sigma Chemical Co., St. Louis, MO), 5 g of bovine serum albumin fraction V (Sigma Chemical Co.), 10 g of yeast extract (Difco Laboratories, Detroit, MI), 0.4 g of L-cysteine HCI (Fisher Scientific Co., Fairlawn, NJ), and 0.25 g of ferric pyrophosphate (Sigma Chemical Co.) adjusted to pH 6.9 with 10 N KOH, and filter-sterilized.
RPMI 1640 with L-glutamine (Gibco Laboratories, Grand Island, NY) was mixed with penicillin (100 U/ml) and streptomycin (100 yg/ ml) (Gibco Laboratories). Egg yolk buffer (EYB) with or without 1% bovine serum albumin (BSA, Miles Laboratories Inc., Naperville, IL) was prepared as previously described (1) .
Agar. Modified charcoal yeast extract agar (CYEA) was prepared as described (1) . Modified CYEA without cysteine and tryptic soy agar with 5% sheep blood were used to assay for contaminating bacteria.
Bacteria. L. pneumophila, Philadelphia 1 strain (serogroup 1), was grown in embryonated hens' eggs, harvested, tested for viability, tested for the presence of contaminating bacteria, passed one time only on CYEA, washed with EYB; flash frozen in aliquots of 10" colony-forming units (CFU)/ml, and stored at -70°C (1) . Before use in the aerosol inoculation system, a stock preparation ofbacteria was diluted in EYB to the desired concentration.
An isogenic pair of L. pneumophila, Philadelphia 1 strain, one of which is MSP-positive (MSP+) (LS2029) and one of which is MSPnegative (MSP-) (LS2102) (18) , and an avirulent mutant L. pneumophila, Philadelphia I strain (16), were grown on CYEA, washed with EYB, flash frozen in aliquots of 10" CFU/ml, stored at -70°C, and tested for the presence of contaminating bacteria as previously de- scribed (1) . The MSP-strain was constructed by Howard Shuman and Lisa Szeto (Columbia University) by inserting transposon Tn9 in the structural gene for MSP, mspA, in an Escherichia coli host strain and subsequently transferring the insertion to the genome of the parental MSP+ strain (LS2029), as previously described (18) .
Membranes. Membranes were prepared from wild-type L. pneumophila, MSP-L. pneumophila, and MSP+ L. pneumophila as previously described with the following modifications (20) . Briefly, bacteria were grown in AYE broth to an optical density (OD) of 1.0 at 540 nm, harvested by centrifugation at 1 1,000 g for 10 min at 4°C, washed in 50 mM Tris, pH 7.5, and then resuspended in 9.5 ml of 0.2 M Tris, 0.5 M sucrose, pH 8.0. The bacteria were first incubated with 100 IO of 0.1 M EDTA, pH 8.0, subsequently incubated with lysozyme (Sigma Chemical Co.) to a final concentration of 0.1 mg/ml, and then diluted in 10 ml of double-distilled water. After 20 min, the suspension was centrifuged at 5,000 gfor 10 min at 4°C. The pellet was resuspended in 400 Ml of 50 mM Tris, 20 mM MgSO4, pH 7.4, added to 100 ml of 5 mM EDTA, pH 8.0, and stirred on ice for 20 min. Then 5 ml of I M Tris, pH 7.4, 2 ml of I M MgSO4, and 200 Ml of I mg/ml DNase I (Sigma Chemical Co.) were added. After 10 min on ice and 10 min at room temperature, the suspension was centrifuged at 5,000 g for 5 min at 4°C, and the pellet discarded. The bacterial membranes in the suspension were collected by centrifugation at 178,000 g for 110 min at 4°C and enumerated in a Petroff-Hausser chamber.
Formalin-killed L. pneumophila. Formalin-killed wild-type L. pneumophila (FKLP) was prepared as previously described (5) .
Animals. Male Hartley strain guinea pigs weighing 250-300 g (Simonson Laboratories, Gilroy, CA), were cared for as previously described (16) . They were observed in the vivarium for 1 wk before challenge with L. pneumophila to ensure that they were healthy. No illnesses or deaths occurred in the guinea pigs before challenge.
Immunization ofguinea pigs by aerosol. Guinea pigs were immunized by exposure to aerosols containing bacteria or membranes in the same lucite aerosol chamber described in detail in a previous study (15) . Guinea pigs were immunized with an aerosol generated from a l0-ml suspension containing one of the following: 2. Protective immunity. Guinea pigs were challenged 3 wk after immunization with a 100% lethal dose of wild-type L. pneumophila. This dose, which was generated from a 10-ml suspension of wild-type L. pneumophila containing 2.5 x 10' CFU/ml, was the lowest dose that consistently resulted in the death of nonimmunized guinea pigs, as previously described (15) . After challenge, animals were held in filtertop cages for I wk. During this time they were observed for signs of illness, and survival was quantitated. Differences in survival between immunized and control animals were evaluated by the Fisher's Exact Test, two-tailed.
Immunoblot analysis of L. pneumophila membranes for MSP. Wild-type L. pneumophila membranes were examined for the presence of MSP by immunoblot analysis (21, 22) , using the alkaline phosphatase technique for immunostaining (23 The capacity ofL. pneumophila membranes to induce protective immunity is independent ofMSP. As noted in the introduction, L. pneumophila MSP is a potent protective immunogen. To examine the possibility that MSP associated with L. pneumophila membranes was responsible for the immunoprotective capacity of the membranes, we examined L. pneumophila membranes for MSP (Fig. 1) .
We first prepared immunoblots of L. pneumophila membranes and probed the blots for the presence of MSP using high-titer anti-MSP antiserum. Whereas anti-MSP antiserum detected as little as 0.01 ,ug MSP in control lanes of the immunoblots (readily visualized on the original ofFig. 1, left, lane C), this antiserum detected no MSP in any preparation ofL. pneumophila membranes (Fig. 1, left, lane D) .
We also investigated whether immunization of guinea pigs with L. pneumophila membranes induced anti-MSP antibody. We immunized guinea pigs with L. pneumophila membranes, collected their sera, and assayed the sera for anti-MSP antibody by immunoblot analysis. Whereas antisera readily reacted with L. pneumophila membranes in the control lane of immunoblots (Fig. 1, right, lane D) , the antisera did not react with even L. pneumophila membranes induce cell-mediated and protective immunity in the absence of an exogenous adjuvant. This suggests that L. pneumophila membranes have intrinsic adjuvanticity. This is consistent with a previous finding that killed L. pneumophila had adjuvant activity comparable to that of killed mycobacteria in promoting humoral immune responses (24) . Our study also suggests that L. pneumophila membranes have adjuvant activity for cell-mediated as well as humoral immune responses.
In contrast to L. pneumophila membranes, FKLP did not induce a strong cell-mediated immune response or induce protective immunity. This suggests that formalin treatment of L. pneumophila modifies its antigenicity in some critical way. Several vaccines against other pathogens are composed of formalin-treated organisms. Our study suggests that such treatment would not be advantageous against L. pneumophila and perhaps other organisms where cell-mediated immune responses are important.
In previous studies, we have shown that two other vaccine preparations induce protective immunity against lethal aerosol challenge with L. pneumophila: an avirulent mutant L. pneumophila and MSP (16, 17 
